Roche presents positive phase III study results for one-dose Xofluza in children with flu

NEXT STORY
Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%
PREV STORY
Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

author_avatar
NASDAQ Market News

Global WholeHealth Partners Corp. (GWHP): The Commentary for Submitting the (EUA) Application # PEUA201789 Date 09/14/2020: for the Global Antigen CoViD19 SARS2 Rapid Test as Mentioned in the 8K Filing on 09/15/20

author_avatar
NASDAQ Market News

Tetra Bio-Pharma and Altus Formulation Sign Joint Venture Agreement for Cannabinoid Drug Product Development

author_avatar
NASDAQ Market News